Rabitec

Country: Unjoni Ewropea

Lingwa: Ingliż

Sors: EMA (European Medicines Agency)

Ixtrih issa

Ingredjent attiv:

attenuated live rabies vaccine virus, strain SPBN GASGAS

Disponibbli minn:

CEVA Santé Animale

Kodiċi ATC:

QI07BD

INN (Isem Internazzjonali):

Rabies vaccine (live, oral) for foxes and raccoon dogs

Grupp terapewtiku:

Red foxes (Vulpes vulpes); Raccoon dogs (Nyctereutes procyonoides)

Żona terapewtika:

Immunologicals for canidae, Live viral vaccines

Indikazzjonijiet terapewtiċi:

For the active immunisation of foxes and raccoon dogs against rabies to prevent infection and mortality.

Sommarju tal-prodott:

Revision: 3

L-istatus ta 'awtorizzazzjoni:

Authorised

Data ta 'l-awtorizzazzjoni:

2017-12-01

Fuljett ta 'informazzjoni

                                B. PACKAGE LEAFLET
15
PACKAGE LEAFLET
RABITEC ORAL SUSPENSION, FOR FOXES AND RACCOON DOGS
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Marketing authorisation holder:
Ceva Santé Animale
10 av. de La Ballastière
33500 Libourne
France
Manufacturer responsible for batch release:
IDT Biologika GmbH
Am Pharmapark
06861 Dessau-Rosslau
Germany
Ceva Tiergesundheit (Riems) GmbH
An der Wiek 7
17493 Greifswald - Insel Riems
Germany
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Rabitec oral suspension for foxes and raccoon dogs
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
1 dose (1.7 ml) embedded in bait contains:
ACTIVE SUBSTANCE:
Attenuated live rabies vaccine virus, strain SPBN GASGAS:
10
6.8
FFU* - 10
8.1
FFU*
(* Focus Forming Units)
The suspension has a yellow colour in a frozen state and a reddish
colour in the liquid state. The baits
are rectangular, brown coloured and have an intensive smell.
4.
INDICATION(S)
For the active immunization of foxes and raccoon dogs against rabies
to prevent infection and
mortality.
Duration of immunity: at least 12 months.
5.
CONTRAINDICATIONS
None.
16
6.
ADVERSE REACTIONS
Not known.
If you notice any side effects, even those not listed in this package
leaflet or you think that the
medicine has not worked, please inform your veterinary surgeon.
7.
TARGET SPECIES
Foxes, raccoon dogs
8.
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
Oral use.
The intake of single bait is sufficient to ensure active immunisation
to prevent infection by rabies
virus. The baits are distributed by land or by air within the
framework of vaccination campaigns
against rabies.
The vaccination area should be as large as possible (preferably larger
than 5,000 km
2
). The vaccination
campaigns in rabies-free areas should be designed in such a way that
the area covers a 50 km belt
ahead of the rabies front. The distribution rate depends on the
topography, on the population density 
                                
                                Aqra d-dokument sħiħ
                                
                            

Karatteristiċi tal-prodott

                                ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
1
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Rabitec oral suspension for foxes and raccoon dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1 dose (1.7 ml) contains:
ACTIVE SUBSTANCE:
Attenuated live rabies vaccine virus, strain SPBN GASGAS:
10
6.8
FFU* - 10
8.1
FFU*
(* Focus Forming Units)
EXCIPIENTS:
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Oral suspension.
The suspension has a yellow colour in a frozen state and a reddish
colour in the liquid state. The baits
are rectangular, brownish coloured and have an intensive smell.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Foxes, raccoon dogs
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the active immunization of foxes and raccoon dogs against rabies
to prevent infection and
mortality.
Duration of immunity: at least 12 months.
4.3
CONTRAINDICATIONS
None.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals:
Vaccine baits are not intended for vaccination of domestic animals.
Gastrointestinal signs (potentially due to the indigestible blister
material) have been reported in dogs
following accidental ingestion of the bait.
2
Special precautions to be taken by the person administering the
veterinary medicinal product to
animals:
Handle the baits with care. It is recommended to wear disposable
rubber gloves when handling and
distributing baits. In case of contact of the vaccine fluid,
immediately remove it by thoroughly rinsing
with water and soap. Seek medical advice immediately and show the
package leaflet or the label to the
physician.
Proposed first aid measures immediately after direct human exposure to
the vaccine fluid should
follow the recommendations of the WHO as outlined in the “WHO Guide
for Rabies Pre- and Post-
Exposure Prophylaxis (PEP) in Humans”.
Since this vaccine has been prepared with live, attenuated
microorganisms, appropriate measures
should be taken to prevent contamination of the handler a
                                
                                Aqra d-dokument sħiħ
                                
                            

Dokumenti f'lingwi oħra

Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Bulgaru 07-01-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Bulgaru 07-01-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Spanjol 07-01-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Spanjol 07-01-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ċek 07-01-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ċek 07-01-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Daniż 07-01-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Daniż 07-01-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ġermaniż 07-01-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ġermaniż 07-01-2021
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ġermaniż 03-04-2020
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Estonjan 07-01-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Estonjan 07-01-2021
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Estonjan 03-04-2020
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Grieg 07-01-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Grieg 07-01-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Franċiż 07-01-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Franċiż 07-01-2021
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Franċiż 03-04-2020
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Taljan 07-01-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Taljan 07-01-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Latvjan 07-01-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Latvjan 07-01-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Litwanjan 07-01-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Litwanjan 07-01-2021
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Litwanjan 03-04-2020
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ungeriż 07-01-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ungeriż 07-01-2021
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ungeriż 03-04-2020
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Malti 07-01-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Malti 07-01-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Olandiż 07-01-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Olandiż 07-01-2021
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Olandiż 03-04-2020
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Pollakk 07-01-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Pollakk 07-01-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Portugiż 07-01-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Portugiż 07-01-2021
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Portugiż 03-04-2020
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Rumen 07-01-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Rumen 07-01-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Slovakk 07-01-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Slovakk 07-01-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Sloven 07-01-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Sloven 07-01-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Finlandiż 07-01-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Finlandiż 07-01-2021
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Finlandiż 03-04-2020
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Svediż 07-01-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Svediż 07-01-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Norveġiż 07-01-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Norveġiż 07-01-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Iżlandiż 07-01-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Iżlandiż 07-01-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Kroat 07-01-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Kroat 07-01-2021

Ara l-istorja tad-dokumenti